Arvinas, Inc. (ARVN) closed the last trading session at $17.70, gaining 0.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...

Shares of Arvinas, Inc. (ARVN) have gained 0.5% over the past four weeks to close the last trading session at $17.67, but there could still be a solid upside left in the stock if short-term price ...

Handelsbanken Fonder AB boosted its stake in shares of Arvinas, Inc. (NASDAQ:ARVN – Free Report) by 16.9% in the fourth quarter, according to the company in its most recent Form 13F filing with ...

ARVN stock opened at $17.50 on Thursday. The firm has a 50-day moving average price of $18.28 and a 200-day moving average price of $22.53. Arvinas has a 12 month low of $15.53 and a 12 month high ...

Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed initial results from a Phase 3 trial for the protein degrader on Tuesday.

Oppenheimer downgraded Arvinas (ARVN) to Perform from Outperform. Effectively assess a stock's risks and opportunities with a clear breakdown of its positive and negative factors. Uncover ...

Arvinas (ARVN) and Pfizer (PFE) announced topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor ...

If that’s not quite your speed, then keep reading. We’ve got a few more top-notch waterproof backpacks to cover your needs. When shopping for waterproof backpacks, it’s important to read ...